Breaking News

AveXis Enters Mfg. Pact for Novel Genetic COVID-19 Vax

AAVCOVID, being developed by U.S. researchers in Massachusetts, leverages adeno-associated viral vector technology to produce immunity.

By: Contract Pharma

Contract Pharma Staff

AveXis, Novartis’s gene therapy unit, has signed a manufacturing agreement to produce a novel genetic COVID-19 vaccine candidate, AAVCOVID, being developed by U.S. researchers in Massachusetts. Massachusetts General Hospital and Massachusetts Eye and Ear are developing a vaccine candidate leveraging adeno-associated viral (AAV) vector technology to produce immunity. The vaccine is in preclinical development with human trials expected in 2020 to determine safety and efficacy. AveXis is cont...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters